The PHEX Transgene Corrects Mineralization Defects in 9-Month-Old Hypophosphatemic Mice
- 12 December 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Calcified Tissue International
- Vol. 84 (2), 126-137
- https://doi.org/10.1007/s00223-008-9201-y
Abstract
Hypophosphatemia is an X-linked dominant disorder resulting from a mutation in the PHEX gene. While osteoblast-specific expression of the PHEX transgene has been reported to decrease the phosphate wasting associated with the disease in male hypophosphatemic (HYP) mice, there are reports that the mineralization defect is only partially corrected in young animals. To test the hypothesis that osteoblast-specific expression of the PHEX gene for a longer time would correct the mineralization defect, this study examined the bones of 9-month-old male and female HYP mice and their wild-type controls with or without expression of the transgene under a collagen type I promoter. Serum phosphate levels, alkaline phosphatase activity, and FGF23 levels were also measured. Mineral analyses based on wide-angle X-ray diffraction, Fourier transform-infrared (FT-IR) spectroscopy, and FT-IR imaging confirmed the decreased mineral content and increased mineral crystal size in male HYP humerii compared to wild-type males and females with or without the transgene and in female HYP mice with or without the transgene. There was a significant increase in mineral content and a decrease in crystallinity in the HYP males’ bones with the transgene, compared to those without. Of interest, expression of the transgene in wild-type animals significantly increased the mineral content in both males and females without having a detectable effect on crystallinity or carbonate content. In contrast to the bones, based on micro-computed tomography and FT-IR imaging, at 9 months there were no significant differences between the HYP and the WT teeth, precluding analysis of the effect of the transgene.Keywords
This publication has 34 references indexed in Scilit:
- MEPE-ASARM Peptides Control Extracellular Matrix Mineralization by Binding to Hydroxyapatite: An Inhibition Regulated by PHEX Cleavage of ASARMJournal of Bone and Mineral Research, 2008
- Degradation of MEPE, DMP1, and Release of SIBLING ASARM-Peptides (Minhibins): ASARM-Peptide(s) Are Directly Responsible for Defective Mineralization in HYPEndocrinology, 2007
- Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp miceAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Aging Increases Stromal/Osteoblastic Cell-Induced Osteoclastogenesis and Alters the Osteoclast Precursor Pool in the MouseJournal of Bone and Mineral Research, 2005
- MEPE has the properties of an osteoblastic phosphatonin and minhibinBone, 2004
- Differential utilization of regulatory domains within the alpha 1(I) collagen promoter in osseous and fibroblastic cells.The Journal of cell biology, 1992
- Microscopic and Crystallographic Examinations of the Teeth of the X-linked Hypophosphatemic MouseJournal of Dental Research, 1989
- Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committeeJournal of Bone and Mineral Research, 1987
- Mineral Uptake by the Femora of Older Female X-Linked Hypophosphatemic (HYP) Mice but not Older Male HYP MicePublished by Ovid Technologies (Wolters Kluwer Health) ,1987
- X-LINKED HYPOPHOSPHATÆMIC RICKETS: INADEQUATE THERAPEUTIC RESPONSE TO 1,25-DIHYDROXYCHOLECALCIFEROLThe Lancet, 1973